Benjamin P. Geisler, M.D., M.P.H.

Publication list

bgeisler@post.harvard.edu • ben-geisler.com

Date prepared: November 5, 2026

70+ peer-reviewed articles, 6 reviews, chapters and editorials, 11 letters to the editor and 70+ conference abstracts and posters. Entries appear newest first within each section.

Peer-reviewed publications

Research investigations

1. Müller M, **Geisler BP**, Shamas S, von Bomhard N, Hoster E, Pfirrmann M, Mansmann U. FAIR by design (TRACE): A Trusted Research Access & Collaboration Environment. BMC Med Inform Decis Mak. 2026;26(1).
2. Yang F, **Geisler BP**, d'Ancona G, Lee B, Jackson DJ, Bloom CI. Prevalence and cost implications of broadening asthma biologic eligibility criteria. World Allergy Organ J. 2026;19(9):101449.
3. Heller M, Marx K, Hoffmann U, Rebettge J, Bader F, Fenves AZ, **Geisler BP**, Wendt R. Urea vs. tolvaptan for hospitalized patients with SIADH. Nephrol Dial Transplant. 2026;gfag165.
4. Satomi K, Soejima K, Kusano K, Myung JE, Tanaka Y, Ryschon AM, **Geisler BP**, Ikeno F, Pietzsch JB. Cost-Effectiveness of Atrioventricular Synchronous Leadless Pacing in Patients With Atrioventricular Block: Results and Implications From an Exploratory Analysis for Japan. Circ Rep. 2026;8(7):1141-50.
5. Ree AH, Bousquet PA, Visnovska T, Lüders T, **Geisler BP**, Wang S, Bordin DL, Nilsen HL, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Berg JP, Flatmark K, Meltzer S. Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer. Br J Cancer. 2026;134(8):1176-82.
6. de Bruin O, Maisonneuve E, Hurley E, Nordeng HME, Bérard A, Sheehy O, Kaul P, Shinde MU, Cosgrove A, Lyons JG, Messenger-Jones E, Kempner ME, Toh S, Hua W, Hernández-Muñoz JJ, Sahin L, Cesta CE, Hägg D, Gini R, Paoletti O, Poblador-Plou B, Jordan S, Thayer D, Rodríguez- Bernal CL, Sánchez-Sáez F, Lassalle R, Bernard MA, Alsina E, Ahmadizar F, Favre G, Panchaud A, Bloemenkamp KWM, Plueschke K, de Vries C, Siiskonen SJ, Sturkenboom MCJM, CONSIGN Collaboration Group. Medications Used Among Nonhospitalized Pregnant Women With COVID-19: A Prospective Individual Patient Data Meta-Analysis in Europe and North America. Pharmacoepidemiol Drug Saf. 2026;35(1):e70303. (*member of the collaboration group, named in an appendix)
7. Choi EY, van Gelder MMHJ, **Geisler BP**, Oh IS, Nordeng HME. Antirheumatic medication use among pregnant women with rheumatoid arthritis: a Norwegian nationwide drug utilisation study. EULAR Rheumatol Open. 2026;2(1):79-89.
8. Gutmann AS, Mandl MM, Rieder C, Hoechter DJ, Dietz K, **Geisler BP**, Boulesteix AL, Tomasi R, Hinske LC. Comparing supervised machine learning algorithms for the prediction of partial arterial pressure of oxygen during craniotomy. BMC Med Inform Decis Mak. 2025;25(1):326.
9. Pietzsch JB, **Geisler BP**, Garner AM, Ryschon AM, Gray WA, Fujihara M, Schneider PA. Clinical and economic implications of focal dissection treatment following percutaneous transluminal angioplasty of the superficial femoral artery: an exploratory analysis based on the TOBA II Study. J Comp Eff Res. 2025;14(1):e240055.
10. Sheikhalishahi S, Kaspar M, Zaghdoudi S, Sander J, Simon P, **Geisler BP**, Lange D, Hinske LC. Predicting Successful Weaning from Mechanical Ventilation by Reduction in Positive End-expiratory Pressure Level Using Machine Learning. PLOS Digit Health. 2024;3(3):e0000478.
11. Hurley E, **Geisler BP**, Lupattelli A, Poblador-Plou B, Lassalle R, Jové J, Bernard MA, Sakr D, Sanfélix-Gimeno G, Sánchez-Saez F, Rodríguez-Bernal CL, Sabaté M, Ballarín E, Aguilera C, Jordan S, Thayer D, Farr I, Ahmed S, Bartolini C, Limoncella G, Paoletti O, Gini R, Maglanoc LA, Dudukina E, Ehrenstein V, Alsina E, Vaz TA, Riera-Arnau J, Sturkenboom MCJM, Nordeng HME. COVID-19 and pregnancy: A European study on pre- and post-infection medication use. Eur J Clin Pharmacol. 2024;80(5):707-16.
12. Heyne TF, Negishi K, Choi DS, Al Saud AA, Marinacci LX, Smithedajkul PY, Devaraj LR, Little BP, Mendoza DP, Flores EJ, Petranovic M, Toal SP, Shokoohi H, Liteplo AS, **Geisler BP**. Handheld Lung Ultrasound to Detect COVID-19 Pneumonia in Inpatients: A Prospective Cohort Study. POCUS J. 2023;8(2):175-83.
13. Devaraj LR, **Geisler BP**, Cooper C, Simpkin Begin A. Impact of COVID-19 Policies on Hospitalists' Psychological Safety. South Med J. 2023;116(9):772-5.
14. **Geisler BP**, Cao KN, Ryschon AM, Alavi K, Komen N, Pietzsch JB. Cost associated with diverting ostomy after rectal cancer surgery: a transnational analysis. Surg Endosc. 2023;37(10):7759-66.

15. Olds PK, Musinguzi N, **Geisler BP**, Sarin P, Haberer JE. Evaluating disparities in code status designation among patients admitted with COVID-19 at a quaternary care center early in the pandemic. Medicine (Baltimore). 2023;102(30):e34447.
16. Tchétché D, de Gennes CD, Cormerais Q, **Geisler BP**, Dutot C, Wilquin-Bequet F, Breau-Brunel M, Lueza B, Pietzsch JB. Cost-effectiveness of transcatheter aortic valve implantation in patients at low surgical risk in France: a model-based analysis of the Evolut LR trial. Eur J Health Econ. 2024;25(3):447-57.
17. Kuo TT, Pham A, Edelson ME, Kim J, Chan J, Gupta Y, Ohno-Machado L, R2D2 Consortium. Blockchain-enabled immutable, distributed, and highly available clinical research activity logging system for federated COVID-19 data analysis from multiple institutions. J Am Med Inform Assoc. 2023;30(6):1167-78. (*role analysis and interpretation of data, named in an appendix)
18. Olds PK, Musinguzi N, **Geisler BP**, Haberer JE. Evaluating disparities by social determinants in hospital admission decisions for patients with COVID-19 quaternary hospital early in the pandemic. Medicine (Baltimore). 2023;102(10):e33178.
19. O'neil JC, **Geisler BP**, Rusinak D, Bassett IV, Triant VA, Mckenzie R, Mattison ML, Baughman AW. Discharge to post-acute care and other predictors of prolonged length of stay during the initial COVID-19 surge: a single site analysis. Int J Qual Health Care. 2023;35(1).
20. Ghosh AK, Demetres MR, **Geisler BP**, Ssebyala SN, Yang T, Shapiro MF, Setoguchi S, Abramson D. Impact of Hurricanes and Associated Extreme Weather Events on Cardiovascular Health: A Scoping Review. Environ Health Perspect. 2022;130(11):116003.
21. Nowatzke J, Guedeney P, Palaskas N, Lehmann L, Ederhy S, Zhu H, Cautela J, Francis S, Courand PY, Deswal A, Ewer SM, Aras M, Arangalage D, Ghafourian K, Fenioux C, Finke D, Peretto G, Zaha V, Itzhaki Ben Zadok O, Tajiri K, Akhter N, Levenson J, Baldassarre L, Power J, Huang S, Collet JP, Moslehi J, Salem JE, International ICI-myocarditis registry contributors. Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry. Eur J Cancer. 2022;177:197-205. (*role supplied data, named in an appendix)
22. Abid MH, Lucier DJ, Hidrue MK, **Geisler BP**. The Effect of Standardized Hospitalist Information Cards on the Patient Experience: a Quasi-Experimental Prospective Cohort Study. J Gen Intern Med. 2022;37(15):3931-6.
23. Pietzsch JB, **Geisler BP**, Manda B, Misra S, Lyden SP, Pflederer TA, Lookstein RA. IN.PACT AV Access Trial: Economic Evaluation of Drug-Coated Balloon Treatment for Dysfunctional Arteriovenous Fistulae Based on 12-Month Clinical Outcomes. J Vasc Interv Radiol. 2022;33(8):895-902.e4.
24. Du S, Mansmann U, **Geisler BP**, Li Y, Hornung R. A Diagnostic Model for Kawasaki Disease Based on Immune Cell Characterization From Blood Samples. Front Pediatr. 2021;9:769937.
25. Pietzsch JB, **Geisler BP**, Iken AR, van Wijck IPS, Holewijn S, Reijnen MMPJ. Cost-Effectiveness of Urea Excipient-Based Drug-Coated Balloons for Chronic Limb-Threatening Ischemia from Femoropopliteal Disease in the Netherlands and Germany. Cardiovasc Intervent Radiol. 2022;45(3):298-305.
26. Pietzsch J, Ederhof M, **Geisler B**, Schneider P. Cost-Effectiveness of Percutaneous Deep Vein Arterialization for Patients With No-Option Chronic Limb-Threatening Ischemia: An Exploratory Analysis Based on the PROMISE I Study. J Crit Limb Ischemia. 2021;1(4):E148-57.
27. O'Neil JC, **Geisler BP**, Rusinak D, Bassett IV, Triant VA, McKenzie R, Mattison ML, Baughman AW. Case management in a COVID-19 surge: A single-institution study of disposition and access to post-acute care. J Am Geriatr Soc. 2022;70(2):372-5.
28. Kim J, Neumann L, Paul P, Day ME, Aratow M, Bell DS, Doctor JN, Hinske LC, Jiang X, Kim KK, Matheny ME, Meeker D, Pletcher MJ, Schilling LM, SooHoo S, Xu H, Zheng K, Ohno-Machado L, R2D2 Consortium. Privacy-protecting, reliable response data discovery using COVID-19 patient observations. J Am Med Inform Assoc. 2021;28(8):1765-76. (*role analysis and interpretation of data, named in an appendix)
29. Ghosh AK, **Geisler BP**, Ibrahim S. Racial/ethnic and socioeconomic variations in hospital length of stay: A state-based analysis. Medicine (Baltimore). 2021;100(20):e25976.
30. Roseleur J, Gonzalez-Chica DA, Bernardo CO, **Geisler BP**, Karnon J, Stocks NP. Blood pressure control in Australian general practice: analysis using general practice records of 1.2 million patients from the MedicineInsight database. J Hypertens. 2021;39(6):1134-42.
31. **Geisler BP**, Kingsley TC, Izmirly PM, Costedoat-Chalumeau N, Roswell RO. Hydroxychloroquine Toxicity: Concurrent Complete Heart Block and Severe Left Ventricular Systolic Dysfunction. A Clinical Image. J Clin Rheumatol. 2021;27(8S):S657-8.

32. Pietzsch JB, **Geisler BP**, Daniels MJ, Busca RM, Tarantini G, Søndergaard L, Kasner SE. An assessment of annual procedure volumes and therapy adoption of transcatheter closure of patent foramen ovale in four European countries. Eur Stroke J. 2021;6(1):72-80.
33. **Geisler BP**, Jørgensen TH, Thyregod HGH, Pietzsch JB, Søndergaard L. Cost-effectiveness of transcatheter versus surgical aortic valve replacement in patients at lower surgical risk: results from the NOTION trial. EuroIntervention. 2019;15(11):e959-67.
34. Kaul V, Bhan R, Stewart NH, Behrens DM, Gutman A, Dangayach N, **Geisler BP**, Carroll CL. Study Comparing Traditional Versus Alternative Metrics to Measure the Impact of the Critical Care Medicine Literature. Crit Care Explor. 2019;1(8):e0028.
35. Upadhyay VA, **Geisler BP**, Sun L, Uhl L, Kaufman RM, Stowell C, Makar RS, Bendapudi PK. Utilizing a PLASMIC score-based approach in the management of suspected immune thrombotic thrombocytopenic purpura: a cost minimization analysis within the Harvard TMA Research Collaborative. Br J Haematol. 2019;186(3):490-8.
36. Pietzsch JB, Richter AK, Randerath W, Steffen A, Liu S, **Geisler BP**, Wasem J, Biermann-Stallwitz J. Clinical and Economic Benefits of Upper Airway Stimulation for Obstructive Sleep Apnea in a European Setting. Respiration. 2019;98(1):38-47.
37. **Geisler BP**, Jilg N, Patton RG, Pietzsch JB. Model to evaluate the impact of hospital-based interventions targeting false-positive blood cultures on economic and clinical outcomes. J Hosp Infect. 2019;102(4):438-44.
38. Pietzsch JB, Busca R, Rott C, **Geisler BP**, Weber SA, Slebos DJ, Deslee G, Herth FJF. Adoption Patterns of Bronchoscopic Lung Volume Reduction Procedures in Germany and Predicted Procedure Volumes for Other European Countries. Respiration. 2019;97(1):34-41.
39. Faucett SC, **Geisler BP**, Chahla J, Krych AJ, Kurzweil PR, Garner AM, Liu S, LaPrade RF, Pietzsch JB. Meniscus Root Repair vs Meniscectomy or Nonoperative Management to Prevent Knee Osteoarthritis After Medial Meniscus Root Tears: Clinical and Economic Effectiveness. Am J Sports Med. 2019;47(3):762-9.
40. Rush B, Tyler PD, Stone DJ, **Geisler BP**, Walley KR, Celi LA. Outcomes of Ventilated Patients With Sepsis Who Undergo Interhospital Transfer: A Nationwide Linked Analysis. Crit Care Med. 2018;46(1):e81-6.
41. Tyler PD, Stone DJ, **Geisler BP**, McLennan S, Celi LA, Rush B. Racial and Geographic Disparities in Interhospital ICU Transfers. Crit Care Med. 2018;46(1):e76-80.
42. Pietzsch JB, **Geisler BP**, Ikeno F. Cost-effectiveness of orbital atherectomy compared to rotational atherectomy in treating patients with severely calcified coronary artery lesions in Japan. Cardiovasc Interv Ther. 2018;33(4):328-36.
43. Feller-Kopman D, Liu S, **Geisler BP**, DeCamp MM, Pietzsch JB. Cost-Effectiveness of a Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. J Thorac Oncol. 2017;12(8):1223-32.
44. **Geisler BP**, Huygens SA, Reardon MJ, Van Mieghem N, Kappetein AP, Osnabrugge RLJ, Pietzsch JB. Cost-Effectiveness and Projected Survival of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement for High Risk Patients in a European Setting: A Dutch Analysis Based on the CoreValve High Risk Trial. Structural Heart. 2017;1(5-6):267-74.
45. Katsanos K, **Geisler BP**, Garner AM, Zayed H, Cleveland T, Pietzsch JB. Economic analysis of endovascular drug-eluting treatments for femoropopliteal artery disease in the UK. BMJ Open. 2016;6(5):e011245.
46. Cohen JN, Coppock A, Ghosh AK, **Geisler BP**. Do Insurers Compete on the Federal Health Insurance Exchange? F1000Res. 2015;4:25.
47. Neumann A, Mostardt S, Biermann J, Gelbrich G, Goehler A, **Geisler BP**, Siebert U, Störk S, Ertl G, Angerrmann CE, Wasem J. Cost-effectiveness and cost-utility of a structured collaborative disease management in the Interdisciplinary Network for Heart Failure (INH) study. Clin Res Cardiol. 2015;104(4):304-9.
48. Pietzsch JB, **Geisler BP**, Garner AM, Zeller T, Jaff MR. Economic analysis of endovascular interventions for femoropopliteal arterial disease: a systematic review and budget impact model for the United States and Germany. Catheter Cardiovasc Interv. 2014;84(4):546-54.
49. **Geisler BP**, Egan BM, Cohen JT, Garner AM, Akehurst RL, Esler MD, Pietzsch JB. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol. 2012;60(14):1271-7.
50. Zonies D, Maier RV, Civil I, Eid A, **Geisler BP**, Guerrero A, Mock C. Trauma and burn education: a global survey. World J Surg. 2012;36(3):548-55.
51. Patterson D, **Geisler BP**, Morse A. Determining health-related quality of life and health state utility values of urinary incontinence in women. Female Pelvic Med Reconstr Surg. 2011;17(6):305-7.

52. Venkatesh AK, **Geisler BP**, Gibson Chambers JJ, Baugh CW, Bohan JS, Schuur JD. Use of observation care in US emergency departments, 2001 to 2008. PLoS One. 2011;6(9):e24326.
53. **Geisler BP**, Schuur JD, Pallin DJ. Estimates of electronic medical records in U.S. Emergency departments. PLoS One. 2010;5(2):e9274.
54. **Geisler BP**, Widerberg KF, Berghöfer A, Willich SN. Leadership in health care: developing a post-merger strategy for Europe's largest university hospital. J Health Organ Manag. 2010;24(3):258-76.
55. Göhler A, Conrads-Frank A, Worrell SS, **Geisler BP**, Halpern EF, Dietz R, Anker SD, Gazelle GS, Siebert U. Decision-analytic evaluation of the clinical effectiveness and cost-effectiveness of management programmes in chronic heart failure. Eur J Heart Fail. 2008;10(10):1026-32.
56. **Geisler BP**, Siebert U, Gazelle GS, Cohen DJ, Göhler A. Deterministic sensitivity analysis for first-order Monte Carlo simulations: a technical note. Value Health. 2009;12(1):96-7.
57. Göhler A, **Geisler BP**, Manne JM, Kosiborod M, Zhang Z, Weintraub WS, Spertus JA, Gazelle GS, Siebert U, Cohen DJ. Utility estimates for decision-analytic modeling in chronic heart failure--health states based on New York Heart Association classes and number of rehospitalizations. Value Health. 2009;12(1):185-7.

Other peer-reviewed publications (including review articles)

1. Wright DE, Kotton CN, **Geisler BP**, Greenwald JL. "You'll be Fine. Probably." Communicating Risk in Clinical Medicine. Mayo Clin Proc. 2026.
2. **Geisler BP**, Holmboe F, Starinieri I, Aas E. Applications of Structural Expert Elicitations for Economic Evaluations: A Systematic Review Update. Pharmacoeconomics. 2026;44(10):1207-24.
3. Uyl-de Groot CA, Xander NSH, Belleman T, Burger EA, Doeswijk R, Durand-Zaleski I, **Geisler BP**, Groene O, Hendrickx A, Henkel PS, Heine R, Huić M, Melli M, Morgan K, Racoviţa M, Quinonez G, Rutten-van Mölken MPMH, Tesař T, Thielen FW, Schneider P, Wu YS, Salcher-Konrad M, Aas E. Bridging affordability and sustainability of health innovations via novel pricing, cost-effectiveness, and reimbursement models to improve patient access: The ASCERTAIN project. Health Policy Technol. 2026;15(2):101155.
4. de Bruin O, Maisonneuve E, Hurley E, Nordeng HME, Bérard A, Sheehy O, Kaul P, Shinde MU, Cosgrove A, Lyons JG, Messenger-Jones E, Kempner ME, Toh S, Hua W, Hernández-Muñoz JJ, Sahin L, Cesta CE, Hägg D, Gini R, Paoletti O, Poblador-Plou B, Jordan S, Rodríguez-Bernal CL, Sánchez-Sáez F, Lassalle R, Bernard MA, Ahmadizar F, Favre G, Panchaud A, Bloemenkamp KWM, Plueschke K, de Vries C, Siiskonen SJ, Sturkenboom MCJM, CONSIGN Collaboration Group. Adverse outcomes among pregnant women with COVID-19 according to hospitalization status: A prospective individual participant data meta-analysis in Europe and North America. Int J Gynaecol Obstet. 2026;173(3):1197-206. (*member of the collaboration group, named in an appendix)
5. Pigat L, **Geisler BP**, Sheikhalishahi S, Sander J, Kaspar M, Schmutz M, Rohr SO, Wild CM, Goss S, Zaghdoudi S, Hinske LC. Predicting Hypoxia Using Machine Learning: Systematic Review. JMIR Med Inform. 2024;12:e50642.
6. Wendt R, Fenves AZ, **Geisler BP**. Use of Urea for the Syndrome of Inappropriate Secretion of Antidiuretic Hormone: A Systematic Review. JAMA Netw Open. 2023;6(10):e2340313.
7. Elsbernd K, Emmert-Fees KMF, Erbe A, Ottobrino V, Kroidl A, Bärnighausen T, **Geisler BP**, Kohler S. Costs and cost-effectiveness of HIV early infant diagnosis in low- and middle-income countries: a scoping review. Infect Dis Poverty. 2022;11(1):82.
8. Asukai Y, Briggs A, Garrison LP, **Geisler BP**, Neumann PJ, Ollendorf DA. Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic. Pharmacoeconomics. 2021;39(11):1201-8.
9. **Geisler BP**, Zahabi L, Lang AE, Eastwood N, Tennant E, Lukic L, Sharon E, Chuang HH, Kang CB, Clayton-Johnson K, Aljaberi A, Yu H, Bui C, Le Mau T, Li WC, Teodorescu D, Hinske LC, Sun DL, Manian FA, Dunn AG. Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review. Syst Rev. 2021;10(1):143.
10. **Geisler BP**, Ji YD, Peacock ZS. Value in Oral and Maxillofacial Surgery: A Systematic Review of Economic Analyses. J Oral Maxillofac Surg. 2017;75(11):2287-303.
11. Heffron SP, Alviar CL, Towe C, **Geisler BP**, Axel L, Galloway AC, Skolnick AH. Dyspnea and Chest Pain in a Young Woman Caused by a Giant Pericardial Lymphohemangioma: Diagnosis and Treatment. Can J Cardiol. 2016;32(10):1260.e23-1260.e25.
12. **Geisler BP**, Raad RA, Esaian D, Sharon E, Schwartz DR. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer. 2015;3:4.

13. Goehler A, **Geisler BP**, Manne JM, Jahn B, Conrads-Frank A, Schnell-Inderst P, Gazelle GS, Siebert U. Decision-analytic models to simulate health outcomes and costs in heart failure: a systematic review. Pharmacoeconomics. 2011;29(9):753-69.
14. **Geisler BP**. Treating anemia in heart failure patients: a review of erythropoiesis-stimulating agents. Expert Opin Biol Ther. 2010;10(8):1209-16.

Non-peer-reviewed publications

Proceedings of meetings and other non-peer-reviewed research publications

1. Becker-Pennrich AS, Mandl MM, Rieder C, Hoechter DJ, Dietz K, **Geisler BP**, Boulesteix AL, Tomasi R, Hinske LC. Comparing supervised machine learning algorithms for the prediction of partial arterial pressure of oxygen during craniotomy. medRxiv (pre-print) June 2022.
2. Heyne TF, **Geisler BP**, Negishi K, Choi D, Al Saud AA, Marinacci LX, Smithedajkul PY, Devaraj LR, Little BP, Mendoza DP, Flores EJ, Petranovic M, Toal SP, Shokoohi H, Liteplo AS. A Simplified Point-of-Care Lung Ultrasound Protocol to Detect Coronavirus Disease 2019 in Inpatients: A Prospective Observational Study. medRxiv (pre-print) April 2021.
3. Kim J, Neumann L, Paul P, Aratow M, Bell DS, Doctor JN, Hinske LC, Jiang X, Kim KK, Matheny ME, Meeker D, Pletcher MJ, Schilling LM, SooHoo S, Xu H, Zheng K, Ohno-Machado L for the R2D2 Consortium. Privacy-Protecting, Reliable Response Data Discovery Using COVID-19 Patient Observations, medRxiv (pre-print). September 23, 2020.
4. Tam HH, Monian B, Rincon B, Celi LA, **Geisler BP**. Prior Statin Use Is Associated with Decreased Mortality and Lower Levels of Liver and Brain Organ Failure Scores in Sepsis - A Matched Observational Study. SSRN Electronic Journal. 2019.
5. **Geisler BP**. ISPOR Student Chapter Activities at Harvard University. ISPOR Student News January-March 2009.
6. **Geisler BP**. We were told we were naive and it would never be possible. Interview with Dr. Robin Coupland from the International Committee of the Red Cross. MSI 11 (2004), 5-7.
7. **Geisler B**, Yossifov K. Scientific Progress: Commercial Interest vs. Ethical Doubts. New Challenges from a Beginning Revolution. Vienna International Model United Nations, Vienna 2001.
8. **Geisler BP**, Akdenizli K, Tannhäuser C, Winkler K. AIDS in Africa. Yearbook of Benjamin Franklin Kolleg, Kröchlendorf and Berlin, June 1999.

Reviews, chapters, monographs and editorials

1. **Geisler BP**, Vergunst F, Ghosh AK. Preparing for the cardiovascular risks of tropical storms amplified by climate change. Eur Heart J. 2026;47(34):4839-41.
2. **Geisler BP**. Perspectives on “early dialogue” between a manufacturer and health technology assessment agencies. Value Health. 2011;14(4):607.
3. **Geisler BP**. Automating First- and Second-order Monte Carlo Simulations for Markov Models in TreeAge Pro. In: Mordechai S, editor. Applications of Monte Carlo Method in Science and Engineering. Rijeka, Croatia: InTech; 2011. p. 917-30.
4. **Geisler BP**. Health state survey-derived utilities in cost-utility analysis--a call to action. Value Health. 2010;13(2):159.
5. **Geisler BP**, Panjabi R. Monitoring Progress in the Largest Project Ever – A Review of “Investing in Development: A Practical Plan to Achieve the Millennium Development Goals.” MSI 12 (2005), 32-39.
6. **Geisler BP**. Why we should help fight tuberculosis. StudentBMJ 11(2003), 479.

Letters to the editor

1. Hoechter DJ, Becker-Pennrich AS, **Geisler BP**, Zwissler B, Irlbeck M, Ramanathan K, Shekar K, Ling RR, Barbaro R, MacLaren G, Fan E, Brodie D. Letter to the editor regarding Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis. Crit Care. 2021;25(1):285.
2. Faucett SC, **Geisler BP**, Chahla J, Krych AJ, LaPrade RF, Pietzsch JB. Should Surgical Repair Be Recommended Over Nonoperative Management for Medial Meniscus Root Tears? Response. Am J Sports Med. 2018;46(9):NP44-5.
3. Feller-Kopman D, Liu S, **Geisler BP**, DeCamp MM, Pietzsch JB. Response to Lee et al. J Thorac Oncol. 2017;12(9):e152-3.
4. **Geisler BP**. Cardiovascular Benefits of the Mediterranean Diet Are Driven by Stroke Reduction and Possibly by Decreased Atrial Fibrillation Incidence. Am J Med. 2016;129(1):e11.

5. **Geisler BP**, Ghosh A. Gabapentin treatment for alcohol dependence. JAMA Intern Med. 2014;174(7):1201.
6. **Geisler BP**, van Dam RM, Gazelle GS, Goehler A. Risk of bias in meta-analysis on erythropoietin-stimulating agents in heart failure. Heart. 2009;95(15):1278-9; author reply 1279.
7. **Geisler BP**, Levin-Scherz JK. Additional factors that could improve cost-effectiveness of pharmacogenetic-guided dosing in warfarin therapy. Ann Intern Med. 2009;151(1):71; author reply 71.
8. **Geisler BP**, Conterio J. Re: Miracle Workers. Letter to the Editor. New York Times Magazine, Mar 2 2008.
9. **Geisler BP**. Re: Diabetes, the Silent Epidemic. New York Times, Jan 19 2006.
10. Kellmeyer P, **Geisler BP**. Re: MacAuley: Systematic Review of Evidence Supporting Preparticipation Physical Examinations for Athletics. StudentBMJ 11 (2003).
11. **Geisler B**, Akdenizli K, Neidhardt A, Ovaska E, Recklinghausen J, Schuster A, Wirth L, Wlodarski M. Twelfth European Students' Conference. McGill J Med. 2001;6(1):3.

Professional educational materials and reports

1. **Geisler BP**, Greenwald JL, Tran KM, editors. 50 Studies Every Hospitalist Should Know. New York, NY: Oxford University Press; 2026.
2. **Geisler BP**, Liao JE, Manian FA. When should hospitalists consider replacing warfarin with a NOAC in their patients on chronic anticoagulation therapy? The Hospitalist August 22, 2018.
3. **Geisler BP**. Author for allergy/immunology questions in SPARK ONE. Online self-assessment tool for hospital medicine professionals; 2016.
4. **Geisler BP**. Psychogenic Purpura (Gardner-Diamond Syndrome). In: Leung LLK, Tirnauer JS, editors. UpToDate. Wellesley, MA: UpToDate; 2007-.

Abstracts, posters and exhibits at professional meetings

1. **Geisler BP**. AI Is Coming for Our Jobs. Accepted for oral presentation at the Nordic Health Economists' Study Group Meeting 2026, Reykjavik, Iceland.
2. **Geisler BP**, Othus M, Meltzer S, Bousquet PA, Burger EA, Aas E, Ree AH. Biomarker signals in MSS/pMMR metastatic colorectal cancer (mCRC) are predominantly prognostic, not predictive – lessons from the randomized METIMMOX trial. Accepted for poster presentation at the European Society for Medical Oncology Congress 2026, Madrid, Spain.
3. **Geisler BP**, Othus M, Meltzer S, Bousquet PA, Burger EA, Ree AH, Aas E. Modeling Multiple Biomarkers in Precision Oncology: How Ignoring Biomarker Correlations Can Reverse Clinical Conclusions. Poster presented at the Society for Medical Decision Making Meeting 2026, Oslo, Norway.
4. **Geisler BP**, Meltzer S, Bousquet PA, Burger EA, Ree AH, Aas E. Cost-Effectiveness of Next Generation Sequencing to Select Microsatellite Stable/Mismatch Repair Proficient Metastatic Colorectal Cancer Patients for Immunecheckpoint Blockade. Poster presented at ISPOR Europe 2024, Barcelona, Spain.
5. **Geisler BP**, Meltzer S, Bousquet PA, Burger EA, Ree AH, Aas E. Value of Immune Checkpoint Blockade (ICB) in Microsatellite Stable/Mismatch Repair Proficient (MSS/pMMR) Metastatic Colorectal Cancer (mCRC). Poster presented at the European Society for Medical Oncology Congress 2024, Barcelona, Spain.
6. Pigat L, **Geisler BP**, Hinske LC. Using Artificial Intelligence for the Prediction of Hypoxia: A Systematic Review. 1. Symposium des Zentrums für Advanced Analytics and Predictive Sciences, University of Augsburg, Germany, October 19, 2022.
7. Becker-Pennrich AS, **Geisler BP**, Niedermayer S, Hinske L. Entwicklung einer Centralen Anaesthesie EventServer ARchitektur (CAESAR) für das OP-Management. 66. GMDS- Jahrestagung / 12. TMF-Jahreskongress. Online 9/2021.
8. Heyne, TF, **Geisler BP**, Negishi K, Choi D, Al Saud A, Marinacci L, Smithedajkul P, Rotman L, Little B, Mendoza D, Flores E, Petranovic M, Toal S, Shokoohi H, Liteplo A. Diagnostic Accuracy of Handheld Lung Ultrasound for Detecting COVID-19. MGH Clinical Research day, Boston MA, 10/2020.
9. Pietzsch JB, Lookstein R, **Geisler BP**, Bharati M, Misra S, Lyden S, Pflederer TA. Drug-Coated Balloons in AV Access: Budget Impact Model based on the IN.PACT AV Access Trial – German and U.S. Health System Perspectives. Leipzig Interventional Course 2020, Leipzig, Germany, 1/2020.
10. Pietzsch JB, Lookstein R, **Geisler BP**, Manda B, Misra S, Lyden S, Pflederer TA. Economic Consequences of Drug-coated Balloon Usage for AV Access based on 12-Month Data from the IN.PACT AV Access Study. Society of Interventional Radiology Annual Meeting, Seattle, WA, 3-4/2020.

11. Reardon MJ, **Geisler BP**, Pietzsch JB, Walton A, Tchétché D, Deeb GM, Yakubov SJ, Popma JJ, Evolut Low Risk Investigators. Evolut Low Risk Trial of self-expanding TAVI vs. SAVR: full 1-year results and economic implications. EuroPOC, Paris/France; 2020.
12. Vedamurthy A, **Geisler B**, Lucier D, Liao J, Loukas B. Leaving Against Medical Advice After The First Episode of Bacteremia Among Persons Who Inject Drugs. Hospital Medicine 2020, San Diego CA, 4/2020.
13. **Geisler BP**, Jilg N, Patton RG, Pietzsch JB. A Model to Evaluate the Impact of Hospital-Based Interventions Targeting False-positive Blood Cultures on Economic and Clinical Outcomes. ISPOR 24th International Meeting, New Orleans LA 5/2019.
14. **Geisler BP**, Pietzsch JB, Gottschalk G, Komen N. Cost of Stoma Management After Diverting Ostomy in Rectal Cancer Patients. Accepted for presentation at 13th European Colorectal Congress, St. Gallen, Switzerland, 12/2019.
15. Reardon MJ, **Geisler BP**, Popma, JJ, van Mieghem NM, Serruys P, Deeb GM, Windecker S, Yakubov SJ, Søndergaard L, Pietzsch JB. Cost-effectiveness of Transcatheter Aortic Valve Implantation in Patients at Intermediate Surgical Risk. A Model-based Analysis based on the SURTAVI Trial Using Contemporary Cost Data. EuroPCR 2019, Paris, France 5/2019.
16. Teirstein PS, **Geisler BP**, Reardon MJ, Pietzsch JB. Cost-Effectiveness of Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk: Initial Results Based on One-year Outcomes from the Evolut Low Risk Trial. TCT 2019, San Francisco, CA 9/2019.
17. Bosmans J, **Geisler BP**, Pietzsch JB. Cost-Effectiveness of Transcatheter Heart Valve Implantation (TAVI) in Patients at High Surgical Risk in the Belgian Healthcare System – An Exploratory Analysis using Contemporary Data. Accepted for presentation at LondonValves 2019, London, UK 11/2019.
18. Pietzsch JB, **Geisler BP**. Costs of Stoma Management Post Colorectal Surgery in the UK Healthcare System and Implications of Potential Reduction in Need for Ostomy Placement. Accepted for presentation at ISPOR Europe, Copenhagen, Denmark, 11/2019.
19. Reardon MJ, **Geisler BP**, Pietzsch JB. Evolution of Length of Stay in TAVI Patients in the US, Germany, and the UK in the period 2013-17: Country-specific Observations and Implications for Health-Economic Analysis. Accepted for presentation at LondonValves 2019, London, UK 11/2019.
20. Sanchez CE, **Geisler BP**, Ederhof M, Pietzsch JB. Frequency and Consequences of Adverse Events After Transcatheter or Surgical Aortic Valve Replacement in Medicare Beneficiaries. TVT 2019 Structural Heart Summit, Chicago 6/2019.
21. Pietzsch JB, Zhang AQ, **Geisler BP**. Transcatheter Aortic Valve Implantation Using Medtronic Evolut R Versus Medtronic CoreValve in Australia. A Model-based Cost-effectiveness Analysis. TCT 2019, San Francisco, CA 9/2019.
22. Pietzsch JB, **Geisler BP**, Schmieder RE. Cost-effectiveness Analysis of Next Generation Renal Denervation Therapy Devices: Threshold Analysis and Projections of the SPYRAL-HTN ON MED Trial for Germany. ISPOR Europe Barceloa, Spain 11/2018.
23. Pietzsch JB, **Geisler B**, Shroff A. Cost-Effectiveness of Orbital compared to Rotational Atherectomy of Severely Calcified Coronary Artery Lesions from a U.S. Payer Perspective. Society for Cardiovascular Angiography and Interventions meeting 2018 (accepted as "best of the best" abstract).
24. Sondergaard L, **Geisler BP**, Jorgensen TH, Thyregod HG, Pietzsch JB. Cost-effectiveness of transcatheter vs surgical aortic valve replacement in patients at lower surgical risk. EuroPCR 2018, Paris, France 5/2018.
25. Pietzsch JB, Garner AM, Hosotani M, **Geisler BP**, Yokoi H. Economic Analysis of Urea-Excipient Drug-Coated Balloon Therapy for Treatment of Femoropopliteal Artery Disease in Japan. ISPOR Asia Pacific 2018, Tokyo, Japan, 7/2018.
26. Pietzsch JB, Weschenfelder AK, Randerath W, Steffen A, Liu S, **Geisler BP**, Wasem J, Biermann- Stallwitz L. Klinische und ökonomische Effekte der Hypoglossusnervstimulation bei obstruktiver Schlafapnoe. 89. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e.V.At: Lübeck, Germany 5/2018.
27. **Geisler BP**, Weber S, Pietzsch M, Zeller T, Pietzsch JB. Trends in Utilization of Endovascular Arterial Revascularizations Modalities Below the Knee in Germany 2009-16. ISPOR 23rd International Meeting, Baltimore, MD 5/2018.
28. Pietzsch JB, Weschenfelder AK, Randerath W, Steffen A, Liu S, **Geisler BP**, Wasem J, Biermann- Stallwitz L. Clinical and Economic Benefit of Upper Airway Stimulation for Obstructive Sleep Apnea in the German Setting. ISPOR 22nd International Meeting, Boston, MA 5/2017.

29. Feller-Kopman D, Liu S, **Geisler BP**, DeCamp NM, Pietzsch JB. Cost-effectiveness of a Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. ISPOR 22nd International Meeting, Boston, MA 5/2017.
30. Michishita I, **Geisler BP**, Ikeno F, Pietzsch JV. Cost-effectiveness of Orbital Compared to Rotational Atherectomy of Severely Calcified Coronary Artery Lesions in Japan. ISPOR 22nd International Meeting, Boston, MA 5/2017.
31. **Geisler BP**. Long-term Clinical and Economic Outcomes of Intensive vs Standard Blood Pressure Reduction in Non-diabetics at High Cardiovascular Risk – Extrapolations from the SPRINT Trial. Society for Hospital Medicine, Las Vegas NV 5/2017.
32. **Geisler BP**. Long-term Clinical and Economic Outcomes of Intensive vs Standard Blood Pressure Reduction in Non-diabetics at High Cardiovascular Risk – Extrapolations from the SPRINT Trial. ISPOR 22nd International Meeting, Boston, MA 5/2017.
33. **Geisler BP**. Prior Statin Use Might be Associated With Lower Sepsis Mortality – Results from a "Big Data" Study. Society for Hospital Medicine, Las Vegas NV 5/2017.
34. **Geisler BP**. Utilization and Cost Effectiveness of a Risk Stratified Diagnostic Approach to Patients with Suspected Thrombotic Thrombocytopenic Purpura. Society for Hospital Medicine, Las Vegas NV 5/2017.
35. **Geisler BP**, Osnabrugge RL, Huygens SA, Reardon MJ, Kappetein AP, Pietzsch JB. Cost- Effectiveness of Transcatheter Aortic Valve Implantation versus Surgical Aortic Valve Replacement: the CoreValve High Risk Trial from a European Perspective. ISPOR 21st Annual International Meeting, Washington, DC, 5/2016.
36. **Geisler B**, Osnabrugge R, Huygens S, Reardon M, Kappetein AP, Pietzsch J. Cost-Effectiveness of Transcatheter Aortic Valve Implantation versus Surgical Aortic Valve Replacement: the CoreValve High Risk Trial from a European Perspective. EuroPCR 2016, Paris, France, 5/2016.
37. Schmieder RE, **Geisler BP**, Egan BM, Pietzsch BP. Cost-Effectiveness Threshold Analysis of Various Age and Systolic Blood Pressure Reduction Scenarios for Renal Denervation Therapy. EuroPCR 2016, Paris, France 5/2016.
38. Pietzsch JB, **Geisler BP**, Garner AM, Zayed H, Cleveland T, Katsanos K. Economic Analysis of drug-coated Balloons and other Endovascular Treatments for Femoropoliteal Artery Disease in the United Kingdom. ISPOR 21st Annual International Meeting, Washington, DC, 5/2016.
39. Pietzsch JB, **Geisler BP**, Jaff MR, Brodmann M. Economic analysis off endovascular interventions for the treatment of femoral popliteal peripheral artery disease in Austria. 19th Annual European Congress, Vienna 10/2016.
40. Pietzsch JB Busca R, **Geisler BP**. Adoption Of Transcatheter Aortic Valve Replacement In Germany: Utilization Patterns And Case Volumes Compared To Surgical Aortic Valve Replacement In The Period 2009-2013. Value in Health. 2015;18(7):A370.
41. Alviar C, Singh P, Vorsanger M, Lee D, **Geisler BP**, Vlodarsky A, Roswell R. COMPARATIVE SAFETY OF INTRAVENOUS NICARDIPINE INFUSION IN PATIENTS WITH AND WITHOUT SYSTOLIC DYSFUNCTION. Journal of the American College of Cardiology. 2015;65(10):A875.
42. Busca R, **Geisler BP**, Pietzsch JB. Cost-Effectiveness of Transcatheter Aortic Valve Replacement: Current Decision-Analytic Models and Future Opportunities. Value in Health. 2015;18(7):A359.
43. Pietzsch JB, **Geisler BP**, Zeller T. Endovascular Interventions For Treatment Of Femoropopliteal Peripheral Artery Disease: Updated Budget Impact Analysis For Germany Based On Latest Clincal Evidence. Value in Health. 2015;18(7):A349.
44. **Geisler BP**, Busca R, Pietzsch JB. TCT-157 The Impact of transcatheter aortic valve replacement on therapy utilization and case volumes in Germany, 2009-2013. Journal of the American College of Cardiology. 2015;66(15):B56.
45. Pietzsch JB, **Geisler BP**, Esler MD. Estimated Added Benefit Of Catheter-Based Renal Denervation For Moderate Treatment-Resistant Hypertension: Impact Of Age And Cardiovascular Risk Factors. Value Health. 2014;17(7):A474.
46. Ghosh AK, **Geisler BP**, Yang SK, Miller LH. Changing Knowledge to Practice: Challenges in Implementing a High Value Care Curriculum at a Large Academic Internal Medicine Residency in New York City. Mid-Atlantic Society for General Internal Medicine Regional Conference, New York, NY - 3/14/2014.
47. Pietzsch JB, **Geisler BP**, Esler MD. Estimated added benefit of catheter-based renal denervation for moderate treatment-resistant. ISPOR 17th Annual European Congress 2014.

48. Alviar CL, Heffron S, **Geisler B**, Altszuler D, Augustine M, Adler L, Towe C, Galloway A, Skolnik A. GIANT CARDIAC LYMPHANGIOMA WITH COMPLETE ENCASEMENT OF THE RIGHT CORONARY ARTERY: IMAGING AND THERAPEUTIC APPROACH. Journal of the American College of Cardiology. 2014;63(12):A711.
49. Pietzsch JB, **Geisler BP**. Model-based projection of clinical effectiveness and cost effectiveness of catheter-based renal denervation in moderate treatment-resistant hypertension. Health Technology Assessment International Meeting 2014.
50. Ceballos RM, Sánchez-Kobashi R, Gay-Molina JG, **Geisler B**, Pietzsch JB. Health-economic Assessment of the Use of Catheter-based Renal Denervation in Patients with Resistant Hypertension in Mexico. ISPOR Latin America 2013, Buenos Aires, Argentina. Value Health 16.
51. Jaff MJ, Pietzsch JB, **Geisler BP**, Zeller T. Clinical and Cost Aspects of Drug Elution. The 35th Charing Cross International Symposium, London, UK, April 2013.
52. Sadri H, Pietzsch JB, **Geisler BP**, Padwal R, Vallee M, Feldman R. Cost-effectiveness of Catheter- Based Renal Denervation for Resistant Hypertension – A Canadian Perspective. International Society for Pharmacoeconomics and Outcomes Research 18th Annual International Meeting 2013.
53. Pietzsch JB, **Geisler BP**, Padwall S. Cost-effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension with Diabetes – A Canadian Perspective. 2013 Canadian Hypertension Congress.
54. Pietzsch JB, **Geisler BP**, Esler MD. Gender differences in added benefit of catheter-based renal denervation for resistant hypertension: estimation of unadjusted and quality-adjusted life year gains in males and females. European Society for Cardiology Congress 2013.
55. Zeller T, Pietzsch JB, **Geisler BP**, Jaff MR. How cost- effective is the concept of “leaving nothing behind.” LINC Conference, Leipzig, Germany, January 2013.
56. Pietzsch JB, **Geisler BP**, Egan BM. Model-based Calculation of Cardiovascular Event Reductions after Catheter-based Renal Denervation for Resistant Hypertension based on Age and Pre-treatment Systolic Blood Pressure. The Society for Cardiovascular Angiography and Interventions 2013 Scientific Sessions, Orlando, FL, May 2013.
57. **Geisler BP**, Sharon S, Gharwan H, Cmar JM. Test Characteristics of Imaging Modalities for Suspected Osteomyelitis of the Foot. Juried poster presentation at Society for General Internal Medicine Mid-Atlantic Regional Meeting, Philadelphia, PA, March 2013.
58. Pietzsch JB, **Geisler BP**, Jaff MR. Budget Impact of Drug Eluting Balloons for Intermittent Claudication from Superficial Femoral Artery Disease in the U.S. Health Care System. International Society for Pharmacoeconomics and Outcomes Research 15th Annual European Congress, Berlin, Germany, November 2012.
59. **Geisler BP**, Pietzsch JB. Cost- and Clinical Effectiveness of Catheter-based Renal Denervation for Resistant Hypertension. 14th Biennial Society for Medical Decision Making European Meeting, Oslo, Norway, May 2012.
60. **Geisler BP**, Pietzsch JB. Cost- and Clinical Effectiveness of Catheter-based Renal Denervation for Resistant Hypertension. 14th Biennial SMDM European Meeting, Oslo, Norway, June 2012.
61. Pietzsch JB, **Geisler BP**, Esler MD. EFFICACY AND CLINICAL AND ECONOMIC EFFECTIVENESS IN RESISTANT HYPERTENSIVE SUBGROUPS. In: J Am Coll Cardiol 59(2012):1716.
62. Pietzsch JB, **Geisler BP**, Akehurst RA. Long-term Clinical Effectiveness and Cost-Effectiveness of Catheter-based Renal Denervation in the UK– A Model-based Projection Based on the Symplicity HTN-2 Trial. International Society for Pharmacoeconomics and Outcomes Research 15th Annual European Congress, Berlin, Germany, November 2012.
63. Pietzsch JB, **Geisler BP**, Egan B. Model-based projection of clinical effectiveness and cost effectiveness of catheter-based renal denervation in hypertensive patients with different cardiovascular risk profiles. In: HTAi 2012, Bilbao, Spain, June 2012.
64. **Geisler BP**, Cohen JT, Neumann PJ, Pietzsch JB. New Approaches for Graphing Probabilistic Patient-relevant Health Outcomes: The Case of Renal Denervation for Resistant Hypertension. Poster presentation at ISPOR 17th Annual International Meeting, Washington, DC, June 2012.
65. Pietzsch JB, **Geisler BP**, Jaff MR. The Health Economics of Peripheral Drug-Eluting Balloons: The Potential Budget Impact for United States Healthcare Payers & Providers. Vascular Interventional Advances (VIVA) 12, Las Vegas, NV, October 2012.
66. Pietzsch JB, **Geisler BP**. Health-Economics of Renal Denervation. In: 1st UK Symposium on Renal Denervation, Royal College of Physicians, London, UK, October 2011.
67. **Geisler BP**, Mutter WP, Wright S, Roshan B, Sands K, Brown RS. Adequacy of Dialysis in Inpatients. Institute for Healthcare Improvement Annual Forum 2009.

68. Neumann A, Mostardt S, Gelbrich G, Goehler A, **Geisler B**, Siebert U, Stork S, Ertl G, Angermann C, Wasem J. Cost-effectiveness and cost-utility of a heart failure management program. 7th World Congress (2009), International Health Economics Association.
69. Mostardt S, Neumann A, Gelbrich G, Göhler A, Siebert U, **Geisler B**, Störk S, Ertl G, Angermann C, Wasem J. Gesundheitsökonomische Evaluation der interdisziplinäres Netzwerk Herzinsuffizienz-Studie. Kongress der Deutschen Gesellschaft für Sozialmedizin und Prävention 2009.
70. Miksad RA, **Geisler BP**, Gaughan EM, Wei JL, Brennan DD, Lai KC, Stadler ZK, Gill BM, Lai M, Stuart KE. Modeling Variability in Hepatocellular Carcinoma Growth. In: The Liver Meeting 2009, Boston, MA. Hepatology 50:4(2009);1780.
71. Patorno E, Margulis A, Cai S, Gagne J, **Geisler BP**, Lin SW, Liu W, Palmsten K, Yau WP, Polinski J. PHP9 THE IMPACT OF LEGISLATION AND PRICING ON GENERIC DRUG UTILIZATION: AN ANALYSIS OF 26 COUNTRIES. Value in Health. 2009;12(3):A80.
72. Göhler A, **Geisler BP**, Kim JJ, Bower T, Khan I, Siebert U, Cohen DJ. Erythropoiesis-stimulating Proteins in the Treatment of Anemic Heart Failure Patients – A Cost-utility Analysis. Society for Medical Decision Making Annual Congress; 2008.
73. **Geisler BP**, Siebert U, Gazelle GS, Cohen DJ, Göhler A. Value of Information Analysis on Erythropoiesis-stimulating Agents in Anemic Heart Failure – Gauging the Value of Future Research Directions. Society for Medical Decision Making Annual Congress; 2008.
74. **Geisler BP**, Göhler A. Can Chronic Mental Stress Lead to Chronic Distress Syndrome? Eur J Med Res 2007.
75. Göhler A, **Geisler BP**, Siebert U, Cohen DJ. Cost-Utility Analysis of Erythropoietin Treatment for Anemic Chronic Heart Failure Patients. Circulation 2007; 115 e564.
76. Gohler A, **Geisler BP**, Kosiborod M, Weintraub WS, Spertus J, Siebert U, Cohen DJ. Utility Estimates for Decision-Analytic Modeling in Congestive Heart Failure – Health states based on NYHA Classes and Number of Rehospitalizations. Society for Medical Decision Making Annual Congress; 2007.
77. Keil T, Eberhardt S, **Geisler BP**, Kulp W, Greiner W, Graf von der Schulenburg J, Willich SN. Efficacy and safety of hormone therapy in women with hot flashes. Ital J Public Health 2005; 2 (2 Suppl 1): 250.